FR3074682B1 - COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID - Google Patents

COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID Download PDF

Info

Publication number
FR3074682B1
FR3074682B1 FR1761808A FR1761808A FR3074682B1 FR 3074682 B1 FR3074682 B1 FR 3074682B1 FR 1761808 A FR1761808 A FR 1761808A FR 1761808 A FR1761808 A FR 1761808A FR 3074682 B1 FR3074682 B1 FR 3074682B1
Authority
FR
France
Prior art keywords
amyline
analog
receptor agonist
polyaminoacid
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1761808A
Other languages
French (fr)
Other versions
FR3074682A1 (en
Inventor
You-Ping Chan
Alexandre GEISSLER
Romain Noel
Richard Charvet
Nicolas LAURENT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1761808A priority Critical patent/FR3074682B1/en
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to SG11202005319PA priority patent/SG11202005319PA/en
Priority to AU2018380901A priority patent/AU2018380901A1/en
Priority to US16/213,865 priority patent/US11129877B2/en
Priority to CN201880088465.3A priority patent/CN111683674A/en
Priority to MX2020005916A priority patent/MX2020005916A/en
Priority to PCT/EP2018/083943 priority patent/WO2019110788A1/en
Priority to EP18815677.2A priority patent/EP3740227A1/en
Priority to BR112020011479-0A priority patent/BR112020011479A2/en
Priority to KR1020207019242A priority patent/KR20200106890A/en
Priority to JP2020531134A priority patent/JP2021505616A/en
Priority to CA3084699A priority patent/CA3084699A1/en
Priority to MA051600A priority patent/MA51600A/en
Publication of FR3074682A1 publication Critical patent/FR3074682A1/en
Application granted granted Critical
Publication of FR3074682B1 publication Critical patent/FR3074682B1/en
Priority to IL275146A priority patent/IL275146A/en
Priority to PH12020550804A priority patent/PH12020550804A1/en
Priority to SA520412138A priority patent/SA520412138B1/en
Priority to US17/404,735 priority patent/US20210401943A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline ; b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, ledit co-polyaminoacide étant constitué d'unités glutamiques ou aspartiques et lesdits radicaux hydrophobes Hy étant de formule X suivante : c) caractérisée en ce que la composition ne comprend pas d'une insuline basale dont le point isoélectrique pi est compris entre 5,8 et 8,5. Elle concerne également une composition caractérisée en ce qu'elle comprend en outre une insuline prandiale.The invention relates to a composition in the form of an aqueous solution for injection, the pH of which is between 6.0 and 8.0, comprising at least: a) amylin, an amylin receptor agonist or a analog of amylin; b) a co-polyamino acid carrying carboxylate charges and hydrophobic Hy radicals, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic Hy radicals being of formula X below: c) characterized in that the composition does not comprise a basal insulin whose isoelectric point pi is between 5.8 and 8.5. It also relates to a composition characterized in that it further comprises a mealtime insulin.

FR1761808A 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID Active FR3074682B1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
FR1761808A FR3074682B1 (en) 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
MA051600A MA51600A (en) 2017-12-07 2018-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
US16/213,865 US11129877B2 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
CN201880088465.3A CN111683674A (en) 2017-12-07 2018-12-07 Composition in the form of an injectable aqueous solution comprising an amylin, an amylin agonist receptor or an amylin analog and a copoly amino acid
MX2020005916A MX2020005916A (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid.
PCT/EP2018/083943 WO2019110788A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
EP18815677.2A EP3740227A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
BR112020011479-0A BR112020011479A2 (en) 2017-12-07 2018-12-07 compositions in the form of an aqueous solution for injection characterized by the fact that it comprises amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid
SG11202005319PA SG11202005319PA (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
JP2020531134A JP2021505616A (en) 2017-12-07 2018-12-07 Composition in the form of an aqueous injectable solution containing amyrin, amyrin agonist receptor or amyrin analog and copolyamino acids
CA3084699A CA3084699A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analog and a co-polyamino acid
AU2018380901A AU2018380901A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
KR1020207019242A KR20200106890A (en) 2017-12-07 2018-12-07 Composition in the form of an aqueous solution for injection comprising amylin, amylin agonist receptor or amylin analog and co-polyamino acid
IL275146A IL275146A (en) 2017-12-07 2020-06-04 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
PH12020550804A PH12020550804A1 (en) 2017-12-07 2020-06-04 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
SA520412138A SA520412138B1 (en) 2017-12-07 2020-06-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analog and a co-polyamino acid
US17/404,735 US20210401943A1 (en) 2017-12-07 2021-08-17 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1761808 2017-12-07
FR1761808A FR3074682B1 (en) 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID

Publications (2)

Publication Number Publication Date
FR3074682A1 FR3074682A1 (en) 2019-06-14
FR3074682B1 true FR3074682B1 (en) 2020-01-03

Family

ID=62091960

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1761808A Active FR3074682B1 (en) 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID

Country Status (1)

Country Link
FR (1) FR3074682B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814461B1 (en) * 2012-01-09 2019-07-24 Adocia Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
FR2985429B1 (en) * 2012-01-09 2016-07-29 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS

Also Published As

Publication number Publication date
FR3074682A1 (en) 2019-06-14

Similar Documents

Publication Publication Date Title
FR3001896B1 (en) PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
FR3001895B1 (en) PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
SG11201810937WA (en) Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
MA49678A (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR
BRPI0606142A2 (en) pyy agonists and uses thereof
MA31997B1 (en) Novel insulin derivatives with an extremely delayed action profile
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
BR112017009405A2 (en) antibiotic compositions.
RU2016136530A (en) COMPOSITIONS OF SELENO-ORGANIC COMPOUNDS AND WAYS OF THEIR APPLICATION
EA200800233A1 (en) COMPOSITION OF IMMUNOCONGUAGE
CY1112353T1 (en) METAUTINE PRODUCTS AND THEIR USE
AR078325A1 (en) Aqueous formulation of N- (Cyanophenyl) PIRAZOLCARBOXAMIDA
GEP20207139B (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
BR112015032200A2 (en) antibody-drug conjugate with improved stability, method of preparation, pharmaceutical composition and use thereof
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
MA51600A (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
BR112018014277A2 (en) formulation, and method of preparing an injectable solution of an axl-adc
FR3061023B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3074682B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3074680B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
BR112017015608A2 (en) insulin analogues with selective signaling properties and reduced mitogenicity
FR3083085B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
FR3020952B1 (en) FAST-ACTING INSULIN FORMULATION COMPRISING SUBSTITUTED ANIONIC COMPOUND AND POLYANIONIC COMPOUND
MX2019011867A (en) Pparî³ agonist for treatment of progressive supranuclear palsy.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190614

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

GC Lien (pledge) constituted

Effective date: 20210525

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

RG Lien (pledge) cancelled

Effective date: 20231011

PLFP Fee payment

Year of fee payment: 7